Vesugen — Research, Dosing & Price Guide

Vesugen is a synthetic tripeptide bioregulator (Lys-Glu-Asp) developed by the Khavinson group targeting vascular tissue. It is classified as a vessel wall bioregulator peptide designed to support and normalize vascular function at the gene expression level. Used in Russian gerontological medicine, vesugen is part of comprehensive vascular health programs for age-related circulatory decline.

Vesugen operates through the same general mechanism as other Khavinson bioregulators — direct interaction with DNA regulatory regions in target cells. It specifically targets vascular smooth muscle and endothelial cells, modulating the expression of genes involved in vessel wall integrity, elastic fiber maintenance, and vascular tone regulation. The tripeptide sequence is proposed to interact with histone proteins and DNA at specific loci, restoring gene expression patterns that shift during aging. This may include upregulation of elastin and collagen synthesis genes in the vessel wall and modulation of matrix metalloproteinase expression to optimize extracellular matrix turnover.

• Khavinson et al. demonstrated that tripeptides of this class can interact with specific DNA sequences and modulate gene expression in cell culture
• Russian gerontological studies show vascular bioregulator courses improve arterial compliance and reduce pulse wave velocity in elderly subjects
• Studies on the broader Khavinson peptide family show tissue-specific effects on gene expression in multiple organ systems
• The peptide has been used in Russian clinical practice for vascular aging for over 15 years

• Standard protocol: 1–2 capsules daily for 10–30 days
• Injectable form: 10 mcg subcutaneously every other day for 10–20 days
• Repeat courses every 3–6 months
• Take capsules on an empty stomach
• Often combined with other vascular and cardiac bioregulators
• Can be integrated into broader anti-aging bioregulator programs

Known Side Effects

• No significant side effects reported
• Ultra-short peptide structure minimizes immunogenicity and toxicity risk
• No cardiovascular adverse events documented
• Long-term safety monitoring data is limited to Russian clinical experience

Safety Profile

Vesugen has been used in Russian clinical practice without significant reported adverse effects. As a tripeptide, it has negligible toxicity and immunogenicity. Safety data is primarily from Russian-language publications and clinical experience rather than large Western randomized controlled trials. No contraindications are established. Compatible with standard cardiovascular medications.

Effects are subtle and cumulative. No dramatic acute effects. Over the course of treatment (10–30 days), vascular function may gradually improve at the cellular level. Measurable effects on vascular parameters may require multiple courses over months. Most beneficial in older individuals with age-related vascular decline. Benefits are proposed to accumulate with repeated courses.

Prices sourced from peptides.gg marketplace. Prices may vary.